Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged biotechnology · clear
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
Written by : Jason J. Jardine and Bailey R. Arenberg Key Takeaway : While recent amendments to Mexico’s patent laws promote faster prosecution and earlier decisions on patents, concerns abound as to the feasibility and integrity of the prosecution…
Written by : J ason J. Jardine and Lizzy T. Do Key Takeaway: Amendments to Mexico’s Federal Law for Protection of Industrial Property align more with U.S. Patent and Trademark Office standards for restoring priority and application revival,…
Written by : Agnes Juang, Ph.D. and Ashley C. Morales Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature.…
Written by : Eric Furman, Ph.D. and Alistair J. McIntyre Key Takeaways : Interference proceedings, though increasingly rare, are heavily evidence-based and determine which party is the first inventor when two or more applicants claim the same patentable…
Written by : Ari Feinstein and Sophia Zahn On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives. The bill, if enacted, would shield certain drug manufacturers who have submitted drug…
Written by : Ari Feinstein and Sophia Zahn On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives. The bill, if enacted, would shield certain drug manufacturers who have submitted drug…
Written by : Robert J. Hilton, Ph.D. and Susan M. Janicki, Ph.D. On November 26, 2025, the United States Patent and Trademark Office (USPTO) issued revised guidelines for determining inventorship of AI-assisted inventions, [1] which is a significant…
Written by : Jason J. Jardine and Geetha Durairaj, Ph.D. In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “ Artificial Intelligence Search Automated Pilot Program ,” or ASAP!, an initiative to identify potential prior…
Written by : Jane Dai, Ph.D . and Geetha Durairaj, Ph.D. On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) revived the Regents of the University of California's (Regents) challenge to the Broad Institute's CRISPR-Cas9…
Written by : Alistair J. McIntyre and Agnes Juang, Ph.D. On March 17, 2025, a bipartisan group of senators introduced two bills intended to decrease the cost of prescription drugs. The sponsors include Chuck Grassley (R-Iowa), John Cornyn (R-Texas),…
Written by : Bailey R. Arenberg and Jason J. Jardine Effective January 28, 2025, the new administration suspended the Climate Change Mitigation Pilot Program (CCMPP) at the United States Patent and Trademark Office (USPTO). [1] The USPTO had instituted…
